NCT00477750 · OUTCOME

Percentage of Participants With Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3)

Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma · Source last updated 2019-10-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: percentage of patients
Interval / dispersion: Not reported
Time frame: Every cycle during treatment up to 3 years

What was measured

The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below.

Analysis population: Patients who experienced an adverse event that is at least possibly related are included in this analysis.

Groups in this outcome

Treatment (Lenalidomide, Melphalan, Prednisone)

Intervention: Drug: lenalidomide 10 mg orally days 1-21 every 28 days until progression Intervention: Drug: melphalan 5mg/m\^2 orally days 1-4 every 28 days until progression Intervention: Drug: prednisone 60mg/m\^2, orally days 1-4 every 28 days until progression

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment (Lenalidomide, Melphalan, Prednisone)	3

Reported measurements

Grade 3

Values in percentage of patients · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Lenalidomide, Melphalan, Prednisone)	33	Not reported	Not reported	Not reported	Not reported

Grade 4

Values in percentage of patients · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Lenalidomide, Melphalan, Prednisone)	67	Not reported	Not reported	Not reported	Not reported

Grade 5

Values in percentage of patients · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
Treatment (Lenalidomide, Melphalan, Prednisone)	0	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
33
title
Grade 3
categories
measurements
group Id
OG000
value
67
title
Grade 4
categories
measurements
group Id
OG000
value
0
title
Grade 5

denoms

counts
group Id
OG000
value
3
units
Participants

description

The overall toxicity rates (percentages) for grade 3 or higher adverse events considered at least possibly related to treatment are reported below.

groups

description
Intervention: Drug: lenalidomide 10 mg orally days 1-21 every 28 days until progression Intervention: Drug: melphalan 5mg/m\^2 orally days 1-4 every 28 days until progression Intervention: Drug: prednisone 60mg/m\^2, orally days 1-4 every 28 days until progression
id
OG000
title
Treatment (Lenalidomide, Melphalan, Prednisone)

param Type

NUMBER

population Description

Patients who experienced an adverse event that is at least possibly related are included in this analysis.

reporting Status

POSTED

time Frame

Every cycle during treatment up to 3 years

title

Percentage of Participants With Toxicity, Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 (v3)

type

SECONDARY

unit Of Measure

percentage of patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice